INM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.85%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

InMed Pharmaceuticals Insider Trading History Chart

InMed Pharmaceuticals Share Price & Price History

^$2.12

▲ +0.039 (1.88%)

As of 04/3/2025 04:53 PM ET

Days: 30 | 90 | 365

InMed Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2024	Andrew Hull	Director	Buy	1,875	$7.80	$14,625.00	1,912
2/20/2024	Eric A. Adams	CEO	Buy	2,080	$7.20	$14,976.00	2,197
4/13/2022	Eric A. Adams	CEO	Buy	428	$17.00	$7,276.00	2,242

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (NASDAQ:INM)

20.12% of InMed Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

InMed Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/14/2025	AdvisorShares Investments LLC	38,460	$0.18M	0.0%	-94.8%	5.342%
2/13/2024	Armistice Capital LLC	205,968	$86K	0.0%	N/A	3.916%
11/14/2022	Armistice Capital LLC	90,000	$0.59M	0.0%	-90.6%	9.605%
5/17/2022	Empery Asset Management LP	61,741	$58K	0.3%	N/A	0.437%
8/17/2021	Armistice Capital LLC	890,000	$2.83M	0.1%	+278.7%	9.954%
8/12/2021	Penserra Capital Management LLC	19,912	$49K	0.0%	N/A	0.223%
5/21/2021	Citadel Advisors LLC	17,211	$57K	0.0%	N/A	0.214%
5/18/2021	Citadel Advisors LLC	17,211	$57K	0.0%	N/A	0.214%
5/17/2021	Armistice Capital LLC	235,000	$0.78M	0.0%	N/A	2.919%

Data available starting January 2016

See Full Table

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Today's Range

Now: $2.12

$2.08

$2.13

50 Day Range

MA: $2.93

$2.06

$4.22

52 Week Range

Now: $2.12

$1.99

$15.70

Volume

31,146 shs

Average Volume

228,260 shs

Market Capitalization

$2.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.18

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?: InMed Pharmaceuticals' top insider investors include:
Eric A Adams (CEO)
Andrew Hull (Director)
Learn More about top insider investors at InMed Pharmaceuticals.